The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent
Authors:
Open Access
- 24 October 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0184501
Abstract
TW-37 is a novel, potent and non-peptide Bcl-2 small-molecule inhibitor. Its activity in colorectal cancer (CRC) cells is studied. In both HCT-116 cells and primary human colon cancer cells, treatment with TW-37 at only nM concentration efficiently inhibited cell survival and proliferation. TW-37 also induced caspase-3/9 and apoptosis activation in CRC cells. Feedback autophagy activation was observed in TW-37-treated CRC cells. Reversely pharmacological autophagy inhibition or Beclin-1 knockdown by targeted-shRNA potentiated TW-37-induced apoptosis and killing of CRC cells. In vivo, intravenous injection of TW-37 inhibited HCT-116 tumor growth in mice. TW-37’s anti-tumor activity was further potentiated against Beclin-1-silenced HCT-116 tumors. Together, targeting Bcl-2 family protein by TW-37 efficiently inhibits CRC cell growth in vitro and in vivo. Inhibition of feedback autophagy activation could further sensitize TW-37.Keywords
Funding Information
- Basic Biomedical Research Fund of the Third Military Medical University (03155-2)
This publication has 35 references indexed in Scilit:
- Beclin-1: Autophagic regulator and therapeutic target in cancerThe International Journal of Biochemistry & Cell Biology, 2013
- TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesisMolecular Cancer Therapeutics, 2009
- SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation statusJournal of Hematology & Oncology, 2009
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer TherapyClinical Cancer Research, 2009
- Retracted: TW‐37, a small‐molecule inhibitor of Bcl‐2, inhibits cell growth and invasion in pancreatic cancerInternational Journal of Cancer, 2008
- Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetinLife Sciences, 2008
- Bcl-2–family proteins and hematologic malignancies: history and future prospectsBlood, 2008
- Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1Clinical Cancer Research, 2007
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005
- Autophagy as a cell death and tumor suppressor mechanismOncogene, 2004